Work

Phase 1/2 Trial of Anti‐pd‐ligand 1 (durvalumab) +/‐ Lenalidomide in Patients With Cutaneous T Cell Lymphoma: Preliminary Results of Phase 1 and Correlative Studies

Year: 2019

Type: article

Abstract: Introduction: BI-1206 is a fully-human anti-FcγRIIB antagonistic antibody that is thought to work by enhancing the activity and overcoming resistance to anti-CD20 antibody treatments (Roghanian et al., 2015).Methods: BI-1206 is currently being tested in two parallel Phase 1/2a clinical trials CRUKD/16/001 and 17-BI-1206-02, in the UK and the US/EU respectively.CRUKD/16/001 includes patients with FcγRIIB-positive B cell malignancy.The phase 1 comprises a dose escalation to determine the maximum tolerated dose or maximum administered dose, and recommended phase 2 dose (RP2D) of BI-1206, in two parallel arms: 1) BI-1206 administered as a single agent.2) BI-1206 administered in combination with rituximab (not open to recruitment yet).The phase 2a is an expansion phase using the RP2D from each arm.

Source: Hematological Oncology

DOI: 10.1002/hon.205_2631

Authors: C. Querfeld, J. Zain, T. Jovanovic‐Talisman, D.L. Wakefield, S. Kil, R. Estephan, P. Young, J. Sanchez, X. Martinez, T. Stiller, J. Palmer, S.T. Rosen

Institutions: City Of Hope National Medical Center, City of Hope, Beckman Research Institute

Language: English

Topic: Cutaneous lymphoproliferative disorders research

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2953160167

FWCI:

Cites:

Cited by: 1

Related to: 10